Parion Sciences Receives FDA Acceptance of the Investigational New Drug Application for Clinical Testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease


Parion Sciences, Inc.
Paul Boucher, President
919-475-9600
pboucher@parion.com

  • Initiation of Phase 1/2a clinical trial in subjects with dry eye disease expected mid-2014
  • Preclinical data will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) on May 6, 2014

Durham, NC (May 1, 2014) – Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.  Preclinical data that supported this approval will be presented in a poster session at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) on May 6, 2014, in Orlando, Fla.

“The FDA’s acceptance of our IND marks an important milestone in our ophthalmology program, as we advance P-321 into a Phase 1/2a clinical trial in subjects with dry eye disease,” said Paul Boucher, President, Parion Sciences. “Our program focuses on a novel mechanism of action to restore one of the core causes of the disease, the reduced tear film volume.  The potent and long lasting effect of P-321 to hydrate the ocular surface could provide a needed relief to patients suffering from dry eye. We’re excited to begin clinical studies later this year.”

READ THE ENTIRE PRESS RELEASE HERE